HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 47, 36703-36707, November 24, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/47/36703    most recent M004045200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delerive, P. Articles by Staels, B. Search for Related Content PubMed PubMed Citation Articles by Delerive, P. Articles by Staels, B. Social Bookmarking                      What's this?

Induction of IB Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor- Activators^*

Philippe Delerive, Philippe Gervois, Jean-Charles Fruchart, and Bart Staels^§

From the INSERM U325, Département d'Athérosclérose, Institut Pasteur de Lille, 1 rue Pr. Calmette 59019 Lille and Faculté de Pharmacie, Université de Lille II, 59000 Lille, France

Received for publication, May 11, 2000, and in revised form, September 6, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Chronic inflammation is a hallmark of degenerative diseases such as atherosclerosis. Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily, which are expressed in the cells of the atherosclerosic lesion. PPAR ligands have been reported to exert anti-inflammatory activities in different cell types by antagonizing the transcriptional activity of NF-B. In the present study, the influence of PPAR activators on the NF-B signaling pathway was investigated. Our results show that fibrates, synthetic PPAR activators, induced the expression of the inhibitory protein IB in human aortic smooth muscle cells as well as in primary human hepatocytes, whereas neither IB-kinase activity nor the degradation rate of IB were affected. Using PPAR-null mice, we demonstrated that fibrates induced IB in liver in vivo and that this action required PPAR. Furthermore, fibrate treatment induced IB protein expression in the cytoplasm and also enhanced IL-1-induced accumulation of IB protein in the nucleus. These actions of fibrates on IB expression were accompanied by a decrease in NF-B DNA binding activity as demonstrated by electrophoretic mobility shift assays. Taken together, these data provide an additional molecular mechanism for the anti-inflammatory activity of PPAR agonists and reinforce their potential use in the treatment of inflammatory diseases.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

The NF-B family of transcription factors plays a major role in the regulation of the expression of a number of genes implicated in cell growth, inflammation, and apoptosis (1, 2). This NF-B/Rel family consists of five members, c-Rel, p65, Rel B, p50, and p52, which form heterodimeric complexes that are most frequently composed of p50 and p65 proteins. In most non-activated cells, NF-B remains in a cytoplasmic inactive complex through its association with the inhibitory proteins IBs (3). Inducers of NF-B, which include inflammatory cytokines, reactive oxygen species, and viral products, activate a dimeric IB kinase (IKK)¹ complex (4-6), which phosphorylates IB on Ser-32 and Ser-36 leading to subsequent ubiquitination and degradation of IB and release of NF-B proteins (1, 2). Free NF-B dimers translocate to the nucleus where they regulate target gene transcription. NF-B has been suggested to play a crucial role in the pathogenesis of atherosclerosis (7). NF-B was reported to be essential for the proliferation of vascular smooth muscle cells (SMC) (8), and activated NF-B heterodimers are detected in human atherosclerotic lesions (9).

Peroxisome proliferator-activated receptors (PPARs), transcription factors belonging to the nuclear receptor superfamily, have also been reported to be expressed in vascular cells in vitro and in vivo (10-19). To date, three different PPAR subtypes have been identified: PPAR, PPAR/, and PPAR. PPARs regulate gene expression by binding with the retinoid receptor RXR as a heterodimeric partner to specific DNA sequence elements termed PPAR response elements (PPRE) (20). In addition to regulating gene transcription via PPREs, PPARs have recently been shown to modulate gene transcription also by negatively interfering with other transcription factor pathways in a DNA binding-independent manner (18, 21). Among the three different PPARs, PPAR activation has been shown to repress cytokine-induced activation of a number of inflammatory genes such as VCAM-1, COX-2, and IL-6 by negatively interfering with NF-B transcriptional activity (14, 22).

However, the influence of PPAR activators on the different components of the NF-B signaling cascade have not yet been explored. In the present study, we show that fibrates, synthetic PPAR ligands, induce IB expression in a PPAR-dependent manner. By contrast, PPAR agonists do not influence IB degradation nor IKK activity. This induction results in an inhibition of NF-B DNA binding leading to a sharp reduction of the p65-mediated gene activation. These actions may contribute to the anti-inflammatory activities of PPAR ligands.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Cell Culture and Chemical Reagents-- Human aortic SMC (Cascade Biologics, Portland, OR) were cultured in SMC basal medium containing 5% SMC growth supplement (Cascade Biologics). Cells from passages 5-8 were used for the experiments. Human primary hepatocytes were prepared as described previously (23). Wy-14643 was from Chemsyn, Lenexa, KS; fenofibric acid from Laboratoires Fournier, Dijon, France, IL-1 from Genzyme, Cambridge, MD; and ciprofibrate from Sigma, Saint Quentin, France.

IKK Assays-- IKK assays were performed as described previously (24). Briefly, total protein extracts were subjected to immunoprecipitation with anti-NEMO antibody (a kind gift of Dr Israël, Institut Pasteur, France) in TNT buffer (200 mM NaCl, Tris 20 mM, pH 7.5, 1% Triton X-100) and collected on protein A-Sepharose beads. The beads were then washed three times with TNT buffer and three times with kinase buffer (20 mM HEPES, 10 mM MgCl₂, 100 µM Na₃VO₄, 20 mM -glycerophosphate, 2 mM dithiothreitol, 50 mM NaCl, pH 7.5). Kinase reactions were performed for 30 min at 30 °C using 5 µCi of [-³²P]ATP and GST·IB-(1-72) as substrate. The reaction products were analyzed on 10% SDS-polyacrylamide gels and detected by autoradiography.

RNA Analysis-- RNA preparation and Northern blot hybridizations were performed as described previously (25). Human IL-6, IB (26), and 36B4 cDNA fragments were used as probes.

Western Blot Analysis-- Protein extracts were fractionated on 10% polyacrylamide gels under reducing conditions (sample buffer containing 10 mM dithiothreitol, transferred onto nitrocellulose membranes, and probed with various antibodies as stated in figure legends). After incubation with a secondary peroxidase-conjugated antibody, signals were visualized by chemiluminescence (Amersham Pharmacia Biotech).

Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)-- SMC cells (3 × 10⁶) were cultured for 2 or 24 h in SMC medium with Wy-14643 (100 µM) or vehicle (Me₂SO, 0.1%) and were subsequently treated with IL-1 (10 ng/ml) for 1 h. Cells were then harvested, and nuclear extracts were obtained as described previously (27). Nuclear proteins were quantified using the bicinchonic acid assay and stored at 80 °C. For EMSA, an NF-B and an OCT1 double-stranded oligonucleotide (Promega) were end-labeled with [-³²P]ATP using T4 polynucleotide kinase according to standard protocols. 5 µg of nuclear extracts from SMC cells were incubated with 50,000 cpm of labeled probes for 20 min at room temperature in 20 µl of buffer containing 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol, 0.3 µg bovine serum albumin, and 2 µg of poly(dIdC). The reactions were analyzed by electrophoresis in a non-denaturing 5% polyacrylamide gel in 0.5× Tris-borate-EDTA buffer. The gels were then dried and exposed at 80 °C for autoradiography.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Recently, it was demonstrated that PPAR activators inhibit IL-1-induced IL-6 secretion by human aortic SMC (HASMC) in a dose-dependent manner (14). Furthermore, PPAR activators negatively regulate IL-1-induced-IL-6 production at the gene expression level by inhibiting NF-B transcriptional activity (21). Activation of the transcription factor NF-B is controlled by a cytokine-activated protein kinase complex, which phosphorylates IB, triggering its polyubiquitination (5). Because PPAR agonists negatively interfere with IL-1-induced NF-B transcriptional activity in HASMC, we investigated whether PPAR activators influence IL-1-induced IKK activity in these cells. IKK activity was very low in non-stimulated HASMC treated with or without the PPAR ligand Wy-14643 (Fig. 1A). Treatment with IL-1 for 10 min resulted in a strong induction of IKK activity. This induction was not affected by preincubation with the PPAR activator Wy-14643 for 2 h, the time period previously reported to inhibit IL-1-induced COX-2 gene expression (14). This result indicates that PPAR activators do not regulate NF-B transcriptional activity by modulating IKK function. Furthermore, we investigated the influence of Wy-14643 on IL-1-induced-IB degradation. Western blot analysis showed that IB protein was degraded within 30 min after IL-1 stimulation, followed by reappearance of the protein at 1 h as previously reported (28) (Fig. 1B). Fibrate treatment did not affect IB protein degradation, consistent with the absence of any effect on IKK. Taken together, these data indicate that fibrates do not impair NF-B transcriptional activation by modulating IKK activity or IB degradation.

View larger version (55K): [in this window] [in a new window]   Fig. 1.   PPAR activators do not influence IB degradation. A, human aortic SMC (80% confluence) were incubated for 2 h in standard medium with Wy-14643 (100 µM) or vehicle (Me2SO, 0.1%) and were subsequently stimulated with IL-1 (10 ng/ml) for different time periods (min). Cytoplasmic extracts were prepared and subjected to IKK assay as described previously (46). B, human aortic SMC (80% confluence) were incubated for 2 h in standard medium with Wy-14643 (100 µM) or vehicle (Me2SO, 0.1%) and were subsequently stimulated with IL-1 (10 ng/ml) for different time periods (min). Total protein extracts were prepared and proteins (50 µg) were separated by SDS-PAGE, transferred to a Hybond membrane, and probed with antibodies to IB and -actin (Santa Cruz Biotechnology).

Next, it was investigated whether PPAR agonists influence IB expression. Incubation of HASMC with IL-1 resulted in the induction of both IL-6 and IB mRNA (Fig. 2A), which is consistent with the previous demonstration that NF-B controls the expression of IB by an inducible autoregulatory loop (28). Wy-14643 alone induced IB mRNA (Fig. 2A), and this effect was further enhanced by IL-1 suggesting that PPAR and IL-1 regulate IB gene expression by different mechanisms. By contrast, Wy-14643 treatment inhibited the induction of IL-6 mRNA levels by IL-1 as described previously (21). Similarly, when incubations were done with fenofibric acid, another PPAR ligand, IB mRNA was significantly induced (Fig. 1B). This induction occurred rapidly with a maximum reached after 1 h. IB mRNA levels declined thereafter but remained elevated to increase again at 24 h (Fig. 2B). Moreover, Wy-14643 increased IB mRNA levels in a dose-dependent manner (Fig. 2C). Results from actinomycin D transcription inhibition experiments demonstrated that fibrates induce IB expression at the transcriptional level (data not shown). In HASMC, Wy-14643 also increased IB protein with a maximum of induction reached after 24 h of treatment (2.25 ± 0.19-fold; p < 0.05), demonstrating that the induction of IB gene expression results in increased protein levels (Fig. 2D).

View larger version (45K): [in this window] [in a new window]   Fig. 2.   PPAR activators induce IB mRNA and protein levels in human aortic SMC. A, human aortic SMC (80% confluence) were incubated for 2 h in standard medium with Wy-14643 (250 µM) or vehicle (Me2SO, 0.1%) and were subsequently stimulated with IL-1 (10 ng/ml) for 3 h. IL-6, IB, and 36B4 mRNA were measured by Northern blot analysis. B, SMC were cultured in standard medium with fenofibric acid (100 µM) for different times as indicated. RNA (10 µg) was extracted, separated on a 1% agarose-formaldehyde gel, transferred to a nylon membrane, and analyzed by hybridization to IB and 36B4 cDNA probes. C, SMC were cultured in standard medium with increasing concentrations of Wy-14643 for 1 h. RNA (10 µg) was extracted, separated on a 1% agarose-formaldehyde gel, transferred to a nylon membrane, and analyzed by hybridization to IB and 36B4 cDNA probes. D, human aortic SMC were cultured in standard medium with Wy-14643 (100 µM) or vehicle (Me2SO, 0.1%) for different lengths of time (h). Protein extracts were prepared, and 30 µg of each extract were separated by SDS-PAGE, transferred to Hybond membrane, and probed with antibodies to IB and -actin.

To determine whether this induction of IB expression by fibrates occurs in other PPAR- expressing cell types, IB regulation was next studied in the liver, where PPAR is highly expressed (29, 30). In line with previous studies (31), human primary hepatocytes express IB mRNA under basal conditions (Fig. 3A). Interestingly, treatment with Wy-14643 increased IB mRNA (approximately 3-fold)(Fig. 3A), indicating that PPAR ligands regulate IB expression also in human primary hepatocytes. Western blot analysis confirmed that Wy-14643 treatment led to IB protein induction in human primary hepatocytes (Fig. 3C). To determine whether IB mRNA induction by fibrates in liver is mediated by PPAR, further studies were performed in PPAR-null mice (32). In livers of PPAR wild-type mice, treatment with the PPAR agonist ciprofibrate resulted in a significant increase (>4-fold) of IB mRNA, whereas in PPARnull mice no induction was observed (Fig. 3B). This result indicates that fibrates regulate IB in liver in a PPAR-dependent manner. Because the liver constitutes a major organ implicated in the synthesis of numerous acute phase proteins such as cytokines and hemostatic factors, whose transcription is under the control of NF-B transcription factors (33, 34), we next studied NF-B target gene regulation by fibrates in human primary hepatocytes. Primary human hepatocytes express basal COX-2 protein levels, which were modestly induced by IL-1 (Fig. 3D). Fibrate treatment dose-dependently inhibited COX-2 expression similarly as described previously in human aortic SMC (14), suggesting a similar role for PPAR in the control of the hepatic inflammatory response.

View larger version (35K): [in this window] [in a new window]   Fig. 3.   Fibrates induce IB mRNA and protein expression in human primary hepatocytes and in livers of PPAR +/+ but not of PPAR / mice. A, human primary hepatocytes were cultured with standard medium supplemented with Wy-14643 (50 µM) or vehicle (Me2SO, 0.1%) for 24 h. RNA (10 µg) was extracted, separated on a 1% agarose-formaldehyde gel, transferred to a nylon membrane, and analyzed by hybridization to IB and 36B4 cDNA probes. B, male PPAR / and +/+ mice (n = 3/group) were fed with rodent chow or rodent chow supplemented with 0.05% ciprofibrate for 2 weeks. At the end of the treatment period, livers were isolated and total RNA was extracted. RNA (10 µg) was separated on 1% agarose, transferred to a nylon membrane, and analyzed by hybridization to IB and 36B4 cDNA probes. Statistical analysis was assessed by analysis of variance (p < 0.05). Statistical significant differences between groups were then evaluated by the Student's t test. C, human primary hepatocytes were cultured with standard medium supplemented with Wy-14643 (50 µM) or vehicle (Me2SO, 0.1%) for 24 h. Protein extracts were prepared and 50 µg of each extract were separated by SDS-PAGE, transferred to Hybond membrane, and probed with antibodies to IB and -actin. D, human primary hepatocytes were cultured with standard medium supplemented with Wy-14643 (50 µM or 100 µM) or vehicle (Me2SO, 0.1%) for 24 h and subsequently stimulated with IL-1 (10 ng/ml) for 16 h. Protein extracts were then prepared, and 50 µg of each extract were separated by SDS-PAGE, transferred to Hybond membrane, and probed with antibodies to COX-2 (a kind gift from Dr Habib, Paris, France) and -actin.

After IB degradation, p50/p65 dimers translocate to the nucleus and activate gene transcription. To explore the functional consequences of IB up-regulation, EMSAs, using a NF-B consensus site probe, were performed. Extracts from non-activated SMC contained a basal NF-B binding activity, which was inhibited by fibrate treatment (Fig. 4A). The presence of NF-B proteins in the complex was verified by shifting the complex using an anti-p65 antibody (data not shown). Treatment with IL-1 resulted in a drastic increase of NF-B binding, which was reduced by Wy-14643 treatment for 2 h and completely abolished after 24-h fibrate pretreatment, whereas binding of OCT1 proteins to their respective consensus site was unaffected (Fig. 4A). As a control, Western blot analysis demonstrated that PPAR activators do not affect either p50 or p65 protein levels (Fig. 4B and data not shown). Poynter and Daynes (35) and Marx et al. (22) showed that PPAR activators significantly reduced NF-B DNA binding activities in aged murine splenocytes and in TNF-stimulated endothelial cells, respectively. Therefore, our data are in line with the findings of these studies and suggest that the inhibition of NF-B DNA binding activities depends on the time of PPAR agonist exposure.

View larger version (38K): [in this window] [in a new window]   Fig. 4.   Wy-14643 reduces IL-1-induced NF-B DNA binding activities in cultured HASMC and increases nuclear IB protein. A, human aortic SMC were cultured for 2 or 24 h with Wy-14643 (100 µM) or vehicle (Me2SO, 0.1%) and were subsequently treated with IL-1 (10 ng/ml) for 1 h. Nuclear proteins were extracted and 5 µg of each sample were subjected to EMSAs using NF-B consensus site or consensus OCT1 site radiolabeled probes (Promega). Complexes were visualized by autoradiography. B, SMC were cultured in standard medium with fenofibric acid (100 µM) or vehicle (Me2SO, 0.1%) for 24 h and subsequently treated with IL-1 (10 ng/ml) for different time intervals (min). Nuclear and cytoplasmic protein extracts were prepared and proteins (20 µg) were separated by SDS-PAGE, transferred to a Hybond membrane, and probed with antibodies to p65. C and D, SMC were cultured in standard medium with Wy-14643 (100 µM) or vehicle (Me2SO, 0.1%) for 24 h and were subsequently treated with or without IL-1 for 1 h. Nuclear (C) and cytoplasmic protein extracts (D) were prepared and proteins (50 µg) were separated by SDS-PAGE, transferred to a Hybond membrane, and probed with antibodies to IB, histone H1, and -actin.

In resting cells, IB sequesters p50/p65 heterodimers in a cytoplasmic inactive complex. To determine whether IB induction modulates NF-B protein translocation, nuclear and cytoplasmic extracts from cultured SMC were isolated. IL-1 induced a rapid but transient p65 translocation to the nucleus (Fig. 4B). Surprisingly, fenofibric acid treatment did not inhibit IL-1-induced p65 translocation suggesting that IB up-regulation by fibrates does not result in an increased sequestration of NF-B in the cytoplasm (Fig. 4B). This result constitutes a major difference between fibrates and glucocorticoids, which were reported to induce IB in T cells and to block p65 translocation (36, 37). Because newly synthesized IB protein accumulates not only in the cytoplasm but also in the nucleus reducing thereby NF-B binding (38, 39), IB protein localization was analyzed in cytoplasmic and nuclear extracts from human aortic SMC after fibrate treatment by Western blot analysis using a monoclonal anti-IB antibody. As a control, fibrate treatment resulted in an increase of the IB cytoplasmic content (Fig. 4D), which is consistent with our findings in Fig. 2D. Surprisingly, in non-stimulated cells, IB protein was also present in the nucleus but its levels were not affected by fibrate treatment (Fig. 4C). IL-1 treatment for 1 h did not result in an increased nuclear content of IB. This finding is in line with a previous study demonstrating that newly synthesized IB protein is only detectable in the nucleus after 2 h of IL-1 or TNF exposure in HeLa S3 cells (39). Interestingly, fibrate treatment in the presence of IL-1 for 1 h led to an increase of nuclear IB protein content (Fig. 4C), which occurs concomitantly with the loss of NF-B DNA binding activity observed in IL-1 treated cells (Fig. 4A).

Several concurring mechanisms may explain the overall anti-inflammatory activities of PPAR ligands. First, PPARs have been shown to down-regulate inflammatory response genes by negatively interfering with the STAT, AP-1, and NF-B transcriptional pathways (14, 18, 21, 40). Direct protein-protein interactions between PPAR and AP-1 and NF-B proteins have been invoked as mechanisms of transrepression (21). Second, by regulating anti-oxidant enzyme activities such as catalase (41), PPAR activators reduce the oxidative stress, and, as such, may inhibit NF-B activation. Finally, the results of the present study provide an additional mechanism through which PPAR activators may antagonize NF-B activation (Fig. 5). Induction of IB mRNA by fibrates may contribute to the inhibition of inflammatory gene activation such as COX-2 or IL-6. The induction of IB by fibrates in cytokine-activated cells should result in an acceleration of NF-B nuclear desactivation. This is consistent with a previous report in which PPAR ligands were shown to affect the duration of the inflammatory response in a PPAR-dependent manner (42). Consistent with this observation, the increase of IB protein after treatment with PPAR activators would lead to a halt in p65-mediated gene activation thereby reducing the duration of the inflammatory response.

View larger version (19K): [in this window] [in a new window]   Fig. 5.   Model of NF-B signaling pathway inhibition by PPAR activators.

The IB promoter contains several regulatory regions among which are sites for NF-B (43, 44). The results using the PPAR-deficient mice indicate that IB activation by fibrates occurs in a PPAR-dependent manner. Our EMSA experiments indicate that PPAR activators do not activate IB transcription in a NF-B-dependent manner because basal NF-B binding activity present in SMC was not increased by Wy-14643 but was conversely lowered. Furthermore, IB mRNA appeared to be synergistically induced by fibrates in the presence of IL-1 (Fig. 2A) suggesting that PPAR activators regulate IB gene expression via a distinct signaling pathway. In addition, PPAR was reported to play a major role in the control of the cellular redox status (35). Klucis et al. (41) reported that administration of PPAR activators results in a drastic increase in the activity of catalase, an anti-oxidant enzyme. This induction occurs in the absence of oxidative stress as demonstrated by the absence of increase of F2-isoprostanes after Wy-14643 treatment (45). Taken together, these observations allow us to exclude that PPAR activators induce an oxidative stress resulting in NF-B activation and induction of IB.

In conclusion, the demonstration that PPAR activators modulate NF-B activation by inducing IB provides an additional, complementary action mechanism contributing to the overall anti-inflammatory properties of PPAR agonists.

	ACKNOWLEDGEMENTS

We thank O. Vidal, B. Derudas, and P. Poulain for technical contributions. We thank Dr. Frank Gonzalez for providing us the PPAR-null mice and Dr. Alain Israël (Pasteur Institute, Paris) who provided us the materials necessary to perform IKK assays.

	FOOTNOTES

^* This work was supported in part by grants from the Institut Pasteur de Lille, INSERM, ARCOL, Laboratoires Fournier, and the Région Nord-Pas-de-Calais/Feder.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by a grant from the Région Nord-Pas-de-Calais.

^§ To whom correspondence should be addressed. Tel.: 33-3-2087-7388; Fax: 33-3-2087-7360; E-mail: Bart.Staels@pasteur-lille.fr.

Published, JBC Papers in Press, September 8, 2000, DOI 10.1074/jbc.M004045200

	ABBREVIATIONS

The abbreviations used are: IKK, IB kinase; SMC, smooth muscle cells; PPAR, peroxisome proliferator-activated receptors; PPRE, PPAR response element; IL, interleukin; GST, glutathione S-transferase; EMSA, electrophoretic mobility shift assay; HASMC, human aortic SMC; STAT, signal transducers and activators of transcription; PAGE, polyacrylamide gel electrophoresis.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. R. Gocke, R. Z. Hussain, Y. Yang, H. Peng, J. Weiner, L.-H. Ben, P. D. Drew, O. Stuve, A. E. Lovett-Racke, and M. K. Racke Transcriptional Modulation of the Immune Response by Peroxisome Proliferator-Activated Receptor-{alpha} Agonists in Autoimmune Disease J. Immunol., April 1, 2009; 182(7): 4479 - 4487. [Abstract] [Full Text] [PDF]

				H. Tiesset, M. Pierre, J.-L. Desseyn, B. Guery, C. Beermann, C. Galabert, F. Gottrand, and M.-O. Husson Dietary (n-3) Polyunsaturated Fatty Acids Affect the Kinetics of Pro- and Antiinflammatory Responses in Mice with Pseudomonas aeruginosa Lung Infection J. Nutr., January 1, 2009; 139(1): 82 - 89. [Abstract] [Full Text] [PDF]

				M. B. Schaefer, A. Pose, J. Ott, M. Hecker, A. Behnk, R. Schulz, N. Weissmann, A. Gunther, W. Seeger, and K. Mayer Peroxisome proliferator-activated receptor-{alpha} reduces inflammation and vascular leakage in a murine model of acute lung injury Eur. Respir. J., November 1, 2008; 32(5): 1344 - 1353. [Abstract] [Full Text] [PDF]

				P. J. H. Smeets, B. E. J. Teunissen, A. Planavila, H. de Vogel-van den Bosch, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPAR{alpha} and PPAR{delta} J. Biol. Chem., October 24, 2008; 283(43): 29109 - 29118. [Abstract] [Full Text] [PDF]

				H. Shen, E. Oesterling, A. Stromberg, M. Toborek, R. MacDonald, and B. Hennig Zinc Deficiency Induces Vascular Pro-Inflammatory Parameters Associated with NF-{kappa}B and PPAR Signaling J. Am. Coll. Nutr., October 1, 2008; 27(5): 577 - 587. [Abstract] [Full Text] [PDF]

				X. Fang, L. Zhang, Y. Feng, Y. Zhao, and J. Dai Immunotoxic Effects of Perfluorononanoic Acid on BALB/c Mice Toxicol. Sci., October 1, 2008; 105(2): 312 - 321. [Abstract] [Full Text] [PDF]

				G. Orasanu, O. Ziouzenkova, P. R. Devchand, V. Nehra, O. Hamdy, E. S. Horton, and J. Plutzky The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice J. Am. Coll. Cardiol., September 2, 2008; 52(10): 869 - 881. [Abstract] [Full Text] [PDF]

				M. Collino, N. S.A. Patel, and C. Thiemermann Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197. [Abstract] [PDF]

				T. Coll, E. Eyre, R. Rodriguez-Calvo, X. Palomer, R. M. Sanchez, M. Merlos, J. C. Laguna, and M. Vazquez-Carrera Oleate Reverses Palmitate-induced Insulin Resistance and Inflammation in Skeletal Muscle Cells J. Biol. Chem., April 25, 2008; 283(17): 11107 - 11116. [Abstract] [Full Text] [PDF]

				C. Linard, O. Gremy, and M. Benderitter Reduction of Peroxisome Proliferation-Activated Receptor {gamma} Expression by {gamma}-Irradiation as a Mechanism Contributing to Inflammatory Response in Rat Colon: Modulation by the 5-Aminosalicylic Acid Agonist J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 911 - 920. [Abstract] [Full Text] [PDF]

				P. Dandona Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342. [Abstract] [Full Text] [PDF]

				S. Cuzzocrea, S. Bruscoli, E. Mazzon, C. Crisafulli, V. Donato, R. Di Paola, E. Velardi, E. Esposito, G. Nocentini, and C. Riccardi Peroxisome Proliferator-Activated Receptor-{alpha} Contributes to the Anti-Inflammatory Activity of Glucocorticoids Mol. Pharmacol., February 1, 2008; 73(2): 323 - 337. [Abstract] [Full Text] [PDF]

				Y. T.Y. Li, K. E. Swales, G. J. Thomas, T. D. Warner, and D. Bishop-Bailey Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2606 - 2611. [Abstract] [Full Text] [PDF]

				H. Lin, C.-C. Hou, C.-F. Cheng, T.-H. Chiu, Y.-H. Hsu, Y.-M. Sue, T.-H. Chen, H.-H. Hou, Y.-C. Chao, T.-H. Cheng, et al. Peroxisomal Proliferator-Activated Receptor-{alpha} Protects Renal Tubular Cells from Doxorubicin-Induced Apoptosis Mol. Pharmacol., November 1, 2007; 72(5): 1238 - 1245. [Abstract] [Full Text] [PDF]

				M. Jana, A. Jana, X. Liu, S. Ghosh, and K. Pahan Involvement of Phosphatidylinositol 3-Kinase-Mediated Up-Regulation of I{kappa}B{alpha} in Anti-Inflammatory Effect of Gemfibrozil in Microglia J. Immunol., September 15, 2007; 179(6): 4142 - 4152. [Abstract] [Full Text] [PDF]

				K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al. Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058. [Abstract] [Full Text] [PDF]

				M. Bunger, H. M. van den Bosch, J. van der Meijde, S. Kersten, G. J. E. J. Hooiveld, and M. Muller Genome-wide analysis of PPAR{alpha} activation in murine small intestine Physiol Genomics, July 18, 2007; 30(2): 192 - 204. [Abstract] [Full Text] [PDF]

				S. Dubrac, P. Stoitzner, D. Pirkebner, A. Elentner, K. Schoonjans, J. Auwerx, S. Saeland, P. Hengster, P. Fritsch, N. Romani, et al. Peroxisome Proliferator-Activated Receptor-{alpha} Activation Inhibits Langerhans Cell Function J. Immunol., April 1, 2007; 178(7): 4362 - 4372. [Abstract] [Full Text] [PDF]

				Y. M. Shah, X. Ma, K. Morimura, I. Kim, and F. J. Gonzalez Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-{kappa}B target gene expression Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G1114 - G1122. [Abstract] [Full Text] [PDF]

				A. Majdalawieh, L. Zhang, and H.-S. Ro Adipocyte Enhancer-binding Protein-1 Promotes Macrophage Inflammatory Responsiveness by Up-Regulating NF-{kappa}B via I{kappa}B{alpha} Negative Regulation Mol. Biol. Cell, March 1, 2007; 18(3): 930 - 942. [Abstract] [Full Text] [PDF]

				K. R. Wagner Modeling Intracerebal Hemorrhage: Glutamate, Nuclear Factor-{kappa}B Signaling and Cytokines Stroke, February 1, 2007; 38(2): 753 - 758. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]

				O. Ziouzenkova, G. Orasanu, G. Sukhova, E. Lau, J. P. Berger, G. Tang, N. I. Krinsky, G. G. Dolnikowski, and J. Plutzky Asymmetric Cleavage of {beta}-Carotene Yields a Transcriptional Repressor of Retinoid X Receptor and Peroxisome Proliferator-Activated Receptor Responses Mol. Endocrinol., January 1, 2007; 21(1): 77 - 88. [Abstract] [Full Text] [PDF]

				T. Kooistra, L. Verschuren, J. de Vries-van der Weij, W. Koenig, K. Toet, H.M.G. Princen, and R. Kleemann Fenofibrate Reduces Atherogenesis in ApoE*3Leiden Mice: Evidence for Multiple Antiatherogenic Effects Besides Lowering Plasma Cholesterol Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2322 - 2330. [Abstract] [Full Text] [PDF]

				S. Cuzzocrea, E. Mazzon, R. Di Paola, A. Peli, A. Bonato, D. Britti, T. Genovese, C. Muia, C. Crisafulli, and A. P. Caputi The role of the peroxisome proliferator-activated receptor-{alpha} (PPAR-{alpha}) in the regulation of acute inflammation J. Leukoc. Biol., May 1, 2006; 79(5): 999 - 1010. [Abstract] [Full Text] [PDF]

				A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF]

				A. S. Paintlia, M. K. Paintlia, I. Singh, and A. K. Singh IL-4-Induced Peroxisome Proliferator-Activated Receptor {gamma} Activation Inhibits NF-{kappa}B Trans Activation in Central Nervous System (CNS) Glial Cells and Protects Oligodendrocyte Progenitors under Neuroinflammatory Disease Conditions: Implication for CNS-Demyelinating Diseases J. Immunol., April 1, 2006; 176(7): 4385 - 4398. [Abstract] [Full Text] [PDF]

				M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke Nuclear Receptors and Autoimmune Disease: The Potential of PPAR Agonists to Treat Multiple Sclerosis J. Nutr., March 1, 2006; 136(3): 700 - 703. [Abstract] [Full Text] [PDF]

				A. Majdalawieh, L. Zhang, I. V. Fuki, D. J. Rader, and H.-S. Ro Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation PNAS, February 14, 2006; 103(7): 2346 - 2351. [Abstract] [Full Text] [PDF]

				X. Fang, S. Hu, B. Xu, G. D. Snyder, S. Harmon, J. Yao, Y. Liu, B. Sangras, J. R. Falck, N. L. Weintraub, et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-{alpha} Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H55 - H63. [Abstract] [Full Text] [PDF]

				W. Chen, W. J. Esselman, D. B. Jump, and J. V. Busik Anti-inflammatory Effect of Docosahexaenoic Acid on Cytokine-Induced Adhesion Molecule Expression in Human Retinal Vascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4342 - 4347. [Abstract] [Full Text] [PDF]

				T. J. Standiford, V. G. Keshamouni, and R. C. Reddy Peroxisome Proliferator-activated Receptor-{gamma} as a Regulator of Lung Inflammation and Repair Proceedings of the ATS, October 1, 2005; 2(3): 226 - 231. [Abstract] [Full Text] [PDF]

				Z Yuan, Y Liu, Y Liu, J Zhang, C Kishimoto, Y Wang, A Ma, and Z Liu Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade Heart, September 1, 2005; 91(9): 1203 - 1208. [Abstract] [Full Text] [PDF]

				S. Li, N. Gokden, M. D. Okusa, R. Bhatt, and D. Portilla Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF Am J Physiol Renal Physiol, August 1, 2005; 289(2): F469 - F480. [Abstract] [Full Text] [PDF]

				X. Fang, S. Hu, T. Watanabe, N. L. Weintraub, G. D. Snyder, J. Yao, Y. Liu, J. Y.-J. Shyy, B. D. Hammock, and A. A. Spector Activation of Peroxisome Proliferator-Activated Receptor {alpha} by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 260 - 270. [Abstract] [Full Text] [PDF]

				E. Dyroy, A. Yndestad, T. Ueland, B. Halvorsen, J. K. Damas, P. Aukrust, and R. K. Berge Antiinflammatory Effects of Tetradecylthioacetic Acid Involve Both Peroxisome Proliferator-Activated Receptor {alpha}-Dependent and -Independent Pathways Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1364 - 1369. [Abstract] [Full Text] [PDF]

				A. Planavila, R. Rodriguez-Calvo, M. Jove, L. Michalik, W. Wahli, J. C. Laguna, and M. Vazquez-Carrera Peroxisome proliferator-activated receptor {beta}/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes Cardiovasc Res, March 1, 2005; 65(4): 832 - 841. [Abstract] [Full Text] [PDF]

				W. Fan, T. Yanase, H. Morinaga, Y.-M. Mu, M. Nomura, T. Okabe, K. Goto, N. Harada, and H. Nawata Activation of Peroxisome Proliferator-Activated Receptor-{gamma} and Retinoid X Receptor Inhibits Aromatase Transcription via Nuclear Factor-{kappa}B Endocrinology, January 1, 2005; 146(1): 85 - 92. [Abstract] [Full Text] [PDF]

				B. Sung, S. Park, B. P. Yu, and H. Y. Chung Modulation of PPAR in Aging, Inflammation, and Calorie Restriction J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2004; 59(10): B997 - B1006. [Abstract] [Full Text] [PDF]

				A. A. Nanji, A. J. Dannenberg, K. Jokelainen, and N. M. Bass Alcoholic Liver Injury in the Rat Is Associated with Reduced Expression of Peroxisome Proliferator-{alpha} (PPAR{alpha})-Regulated Genes and Is Ameliorated by PPAR{alpha} Activation J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 417 - 424. [Abstract] [Full Text] [PDF]

				R. Kleemann, L. Verschuren, B.-J. de Rooij, J. Lindeman, M. M. de Maat, A. J. Szalai, H. M. G. Princen, and T. Kooistra Evidence for anti-inflammatory activity of statins and PPAR{alpha} activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro Blood, June 1, 2004; 103(11): 4188 - 4194. [Abstract] [Full Text] [PDF]

				A. E. Lovett-Racke, R. Z. Hussain, S. Northrop, J. Choy, A. Rocchini, L. Matthes, J. A. Chavis, A. Diab, P. D. Drew, and M. K. Racke Peroxisome Proliferator-Activated Receptor {alpha} Agonists as Therapy for Autoimmune Disease J. Immunol., May 1, 2004; 172(9): 5790 - 5798. [Abstract] [Full Text] [PDF]

				T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-Tomobe, and I. Yamaguchi Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-b pathway J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1481 - 1488. [Abstract] [Full Text] [PDF]

				P. Gervois, R. Kleemann, A. Pilon, F. Percevault, W. Koenig, B. Staels, and T. Kooistra Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-{alpha} Activator Fenofibrate J. Biol. Chem., April 16, 2004; 279(16): 16154 - 16160. [Abstract] [Full Text] [PDF]

				D. N. Muller, J. Theuer, E. Shagdarsuren, E. Kaergel, H. Honeck, J.-K. Park, M. Markovic, E. Barbosa-Sicard, R. Dechend, M. Wellner, et al. A Peroxisome Proliferator-Activated Receptor-{alpha} Activator Induces Renal CYP2C23 Activity and Protects from Angiotensin II-Induced Renal Injury Am. J. Pathol., February 1, 2004; 164(2): 521 - 532. [Abstract] [Full Text] [PDF]

				T.-l. Yue, W. Bao, B. M. Jucker, J.-l. Gu, A. M. Romanic, P. J. Brown, J. Cui, D. T. Thudium, R. Boyce, C. L. Burns-Kurtis, et al. Activation of Peroxisome Proliferator-Activated Receptor-{alpha} Protects the Heart From Ischemia/Reperfusion Injury Circulation, November 11, 2003; 108(19): 2393 - 2399. [Abstract] [Full Text] [PDF]

				O. Ziouzenkova, L. Asatryan, D. Sahady, G. Orasanu, S. Perrey, B. Cutak, T. Hassell, T. E. Akiyama, J. P. Berger, A. Sevanian, et al. Dual Roles for Lipolysis and Oxidation in Peroxisome Proliferation-Activator Receptor Responses to Electronegative Low Density Lipoprotein J. Biol. Chem., October 10, 2003; 278(41): 39874 - 39881. [Abstract] [Full Text] [PDF]

				P. Meerarani, G. Reiterer, M. Toborek, and B. Hennig Zinc Modulates PPAR{gamma} Signaling and Activation of Porcine Endothelial Cells J. Nutr., October 1, 2003; 133(10): 3058 - 3064. [Abstract] [Full Text] [PDF]

				X. Zeng, J. Dai, D. G. Remick, and X. Wang Homocysteine Mediated Expression and Secretion of Monocyte Chemoattractant Protein-1 and Interleukin-8 in Human Monocytes Circ. Res., August 22, 2003; 93(4): 311 - 320. [Abstract] [Full Text] [PDF]

				K. De Bosscher, W. Vanden Berghe, and G. Haegeman The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression Endocr. Rev., August 1, 2003; 24(4): 488 - 522. [Abstract] [Full Text] [PDF]

				G. A. Francis, J.-S. Annicotte, and J. Auwerx PPAR-{alpha} effects on the heart and other vascular tissues Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H1 - H9. [Abstract] [Full Text] [PDF]

				R. Kleemann, P. P. Gervois, L. Verschuren, B. Staels, H. M. G. Princen, and T. Kooistra Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation Blood, January 15, 2003; 101(2): 545 - 551. [Abstract] [Full Text] [PDF]

				R. Cunard, D. DiCampli, D. C. Archer, J. L. Stevenson, M. Ricote, C. K. Glass, and C. J. Kelly WY14,643, a PPAR{alpha} Ligand, Has Profound Effects on Immune Responses In Vivo J. Immunol., December 15, 2002; 169(12): 6806 - 6812. [Abstract] [Full Text] [PDF]

				E. Cernuda-Morollon, F. Rodriguez-Pascual, P. Klatt, S. Lamas, and D. Perez-Sala PPAR Agonists Amplify iNOS Expression While Inhibiting NF-{kappa}B: Implications for Mesangial Cell Activation by Cytokines J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2223 - 2231. [Abstract] [Full Text] [PDF]

				V. Gavrilyuk, C. Dello Russo, M. T. Heneka, D. Pelligrino, G. Weinberg, and D. L. Feinstein Norepinephrine Increases Ikappa Balpha Expression in Astrocytes J. Biol. Chem., August 9, 2002; 277(33): 29662 - 29668. [Abstract] [Full Text] [PDF]

				S. Sethi, O. Ziouzenkova, H. Ni, D. D. Wagner, J. Plutzky, and T. N. Mayadas Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARalpha Blood, July 30, 2002; 100(4): 1340 - 1346. [Abstract] [Full Text] [PDF]

				P. Delerive, K. De Bosscher, W. Vanden Berghe, J.-C. Fruchart, G. Haegeman, and B. Staels DNA Binding-Independent Induction of I{kappa}B{alpha} Gene Transcription by PPAR{alpha} Mol. Endocrinol., May 1, 2002; 16(5): 1029 - 1039. [Abstract] [Full Text] [PDF]

				R. Cunard, M. Ricote, D. DiCampli, D. C. Archer, D. A. Kahn, C. K. Glass, and C. J. Kelly Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors J. Immunol., March 15, 2002; 168(6): 2795 - 2802. [Abstract] [Full Text] [PDF]

				R. B. Clark The role of PPARs in inflammation and immunity J. Leukoc. Biol., March 1, 2002; 71(3): 388 - 400. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Anti-Inflammatory Mechanisms in the Vascular Wall Circ. Res., May 11, 2001; 88(9): 877 - 887. [Abstract] [Full Text] [PDF]

				D. C. Jones, X. Ding, and R. A. Daynes Nuclear Receptor Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Is Expressed in Resting Murine Lymphocytes. THE PPARalpha IN T AND B LYMPHOCYTES IS BOTH TRANSACTIVATION AND TRANSREPRESSION COMPETENT J. Biol. Chem., February 22, 2002; 277(9): 6838 - 6845. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 275/47/36703    most recent M004045200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delerive, P. Articles by Staels, B. Search for Related Content PubMed PubMed Citation Articles by Delerive, P. Articles by Staels, B. Social Bookmarking                      What's this?